Dompé Looks Beyond In-Licensing
Executive SummaryMid-sized Italian drug firm Dompé has made its name as an astute local marketer. Yet the company is now talking up its in-house R&D programs, acknowledging that a pure in-licensing model may not work forever.
You may also be interested in...
Drug pricing and access issues expose the pharmaceutical sector especially acutely to calls for companies to meet ethical and social goals, alongside commercial ones. Digital is up-ending pharma’s processes, its workplaces and its consumers. R&D productivity is spluttering. Amid this turmoil, CEOs highlight company culture – the way an organization behaves – as a crucial ingredient for success. But what is a “right” culture? Organizational culture is neither static nor singular. It is continuously influenced by acquisitions, markets, new technologies and new generations. And pharma’s history suggests that culture change cannot happen without sufficient people change.
ICER’s influence on drug pricing, and policy, is growing. Spotlighting the worst drug price rises is one recent example.